# EDGAR Filing Document

**Accession Number:** 0001082554
**File Stem:** 0001628280-25-036545
**Filing Date:** 2025-7
**Character Count:** 20481
**Document Hash:** 0e317de352a50b102fddbc00e8415222
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-036545.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001628280-25-036545

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250730

**DATE AS OF CHANGE**: 20250730

**EFFECTIVENESS DATE**: 20250730

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNITED THERAPEUTICS Corp
- **CENTRAL INDEX KEY:** 0001082554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521984749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289068
- **FILM NUMBER:** 251163876

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
- **BUSINESS PHONE:** 3016089292

**MAIL ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED THERAPEUTICS CORP
- **DATE OF NAME CHANGE:** 19990324

**As filed with the Securities and Exchange Commission on July 30, 2025**

Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**____________________**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**United Therapeutics Corporation**

(Exact Name of Registrant as Specified in the Charter)

---

| | |
|:---|:---|
| **Delaware** | **52-1984749** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **1000 Spring Street<br>Silver Spring, MD** | <br>**20910** |
| (Address of principal executive offices) | (Zip Code) |

---

**UNITED THERAPEUTICS CORPORATION**

**AMENDED AND RESTATED<br>2015 STOCK INCENTIVE PLAN** 

*(Full title of the plan)*

**Paul A. Mahon, Executive Vice President and General Counsel**

**United Therapeutics Corporation**

**1000 Spring Street**

**Silver Spring, MD 20910<br>(301) 608-9292**<br> *(Name, address and telephone number, including area code, of agent for service)*

**Copy to:**

**Stephen I. Glover, Esq.**

Gibson, Dunn & Crutcher LLP

1700 M Street, N.W.

Washington, D.C. 20036

(202) 955-8500

**John S. Hess, Jr., Esq.**

Executive Vice President and Deputy General Counsel

United Therapeutics Corporation

1735 Connecticut Avenue, N.W.

Washington, D.C. 20009

(202) 483-7000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

------

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**INTRODUCTION**

This Registration Statement on Form S-8 is being filed by United Therapeutics Corporation, a Delaware public benefit corporation (the "Company" or the "Registrant"), in accordance with General Instruction E to Form S-8 relating to 950,000 shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), issuable to eligible individuals under the Company's Amended and Restated 2015 Stock Incentive Plan, which 950,000 shares are in addition to (a) 6,150,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-205309) filed with the Securities and Exchange Commission on June 29, 2015](https://www.sec.gov/Archives/edgar/data/1082554/000110465915048170/a15-14669_2s8.htm)</u>, (b) 2,900,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-225942) filed with the Securities and Exchange Commission on June 28, 2018](https://www.sec.gov/Archives/edgar/data/1082554/000110465918042680/a18-16056_1s8.htm)</u>, (c) 450,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-232906) filed with the Securities and Exchange Commission on July 31, 2019](https://www.sec.gov/Archives/edgar/data/1082554/000110465919042771/a19-13340_1s8.htm)</u>, (d) 500,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-240156) filed with the Securities and Exchange Commission on July 29, 2020](https://www.sec.gov/Archives/edgar/data/1082554/000110465920087597/tm2024980d1_s8.htm)</u>, (e) 1,000,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-258434) filed with the Securities and Exchange Commission on August 4, 2021](https://www.sec.gov/Archives/edgar/data/1082554/000110465921099787/tm2122561d1_s8.htm)</u>, (f) 500,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-266478) filed with the Securities and Exchange Commission on August 3, 2022](https://www.sec.gov/Archives/edgar/data/1082554/000110465922085428/tm2222193d1_s8.htm)</u>, (g) 1,000,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-8 (No. 333-273590) filed with the Securities and Exchange Commission on August 2, 2023](https://www.sec.gov/Archives/edgar/data/1082554/000108255423000026/uthr2023forms-8.htm)</u>, and (h) 1,320,000 shares of Common Stock previously registered on the Registrant's Registration Statement on <u>[Form S-](https://www.sec.gov/Archives/edgar/data/1082554/000108255424000039/uthr2024forms-8.htm)[8 (No. 333-281117) filed with the Securities and Exchange Commission on July](https://www.sec.gov/Archives/edgar/data/1082554/000108255424000039/uthr2024forms-8.htm)[3](https://www.sec.gov/Archives/edgar/data/1082554/000108255424000039/uthr2024forms-8.htm)[1, 2024](https://www.sec.gov/Archives/edgar/data/1082554/000108255424000039/uthr2024forms-8.htm)</u>, in each case together with all exhibits filed therewith or incorporated therein by reference ((a), (b), (c), (d), (e), (f), (g), and (h) collectively, the "Prior Registration Statements"). Except as supplemented by the information set forth herein, the contents of the Prior Registration Statements are incorporated herein by reference.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1082554/000110465921121499/tm2128821d1_ex3-1.htm)</u> | <u>[Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on October 1, 2021)](https://www.sec.gov/Archives/edgar/data/1082554/000110465921121499/tm2128821d1_ex3-1.htm)</u> |
| <u>[4.2](https://www.sec.gov/Archives/edgar/data/1082554/000110465923047912/tm2313121d1_ex3-1.htm)</u> | <u>[Tenth Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on April 21, 2023)](https://www.sec.gov/Archives/edgar/data/1082554/000110465923047912/tm2313121d1_ex3-1.htm)</u> |
| <u>[5.1](uthrex5107302025.htm)</u> | <u>[Opinion of counsel\*](uthrex5107302025.htm)</u> |
| <u>[23.1](uthrex23107302025.htm)</u> | <u>[Consent of Independent Registered Public Accounting Firm\*](uthrex23107302025.htm)</u> |
| <u>[23.2](uthrex5107302025.htm)</u> | <u>[Consent of counsel (included in Exhibit 5.1)\*](uthrex5107302025.htm)</u> |
| <u>[24](#i813e4dc7dd934934a046c585c70f35b0_7)[.1](#i813e4dc7dd934934a046c585c70f35b0_7)</u> | <u>[Power of Attorney (included on signature page)\*](#i813e4dc7dd934934a046c585c70f35b0_7)</u> |
| <u>[99.1](https://www.sec.gov/Archives/edgar/data/1082554/000110465925063287/tm2519194d1_ex10-1.htm)</u> | <u>[United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on June 27, 202](https://www.sec.gov/Archives/edgar/data/1082554/000110465925063287/tm2519194d1_ex10-1.htm)[5](https://www.sec.gov/Archives/edgar/data/1082554/000110465925063287/tm2519194d1_ex10-1.htm)[)](https://www.sec.gov/Archives/edgar/data/1082554/000110465925063287/tm2519194d1_ex10-1.htm)</u> |
| <u>[107](exfilingfees.htm)[.](exfilingfees.htm)[1](exfilingfees.htm)</u> | <u>[Filing Fee Table\*](exfilingfees.htm)</u> |

---

\* Filed herewith

**[SIGNATURES ON THE NEXT PAGE]**

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended (the "Securities Act"), the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Silver Spring, State of Maryland, on this 30th day of July, 2025.

---

| | |
|:---|:---|
| **UNITED THERAPEUTICS CORPORATION** | **UNITED THERAPEUTICS CORPORATION** |
| By: | /s/ Martine A. Rothblatt |
| Martine A. Rothblatt, Ph.D. | Martine A. Rothblatt, Ph.D. |
| Chairperson and Chief Executive Officer | Chairperson and Chief Executive Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**POWER OF ATTORNEY**

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Martine A. Rothblatt, Ph.D., James C. Edgemond and Paul A. Mahon, and each of them, with full power of substitution and full power to act without the others, his or her true and lawful attorney-in-fact and agent, to act for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8, any and all amendments (including post-effective amendments) to this Registration Statement and any subsequent registration statement the Company may hereafter file with the Securities and Exchange Commission pursuant to Rule 462(b) under the Securities Act to register additional awards, and to file this Registration Statement and any subsequent registration statement and all amendments thereto, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in any number of counterparts, each of which shall constitute an original and all of which, taken together, shall constitute one Power of Attorney.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| <u>Name</u> | <u>Title</u> | <u>Date</u> |
| /s/ Martine A. Rothblatt | Chairperson and Chief Executive Officer<br>(Principal Executive Officer) | July 30, 2025 |
| Martine A. Rothblatt, Ph.D. | Chairperson and Chief Executive Officer<br>(Principal Executive Officer) | July 30, 2025 |
| /s/ James C. Edgemond | Chief Financial Officer and Treasurer<br>(Principal Financial Officer and Principal Accounting Officer) | July 30, 2025 |
| James C. Edgemond | Chief Financial Officer and Treasurer<br>(Principal Financial Officer and Principal Accounting Officer) | July 30, 2025 |
| /s/ Christopher Causey | Director | July 30, 2025 |
| Christopher Causey | Director | July 30, 2025 |

---

------

---

| | | |
|:---|:---|:---|
|  | Director | |
| Raymond Dwek | Director |  |
| /s/ Richard Giltner | Director | July 30, 2025 |
| Richard Giltner | Director | July 30, 2025 |
| /s/ Ray Kurzweil | Director | July 30, 2025 |
| Ray Kurzweil | Director | July 30, 2025 |
| /s/ Jan Malcolm | Director | July 30, 2025 |
| Jan Malcolm | Director | July 30, 2025 |
| /s/ Linda Maxwell | Director | July 30, 2025 |
| Linda Maxwell | Director | July 30, 2025 |
| /s/ Nilda Mesa | Director | July 30, 2025 |
| Nilda Mesa | Director | July 30, 2025 |
| /s/ Judy Olian | Director | July 30, 2025 |
| Judy Olian | Director | July 30, 2025 |
| /s/ Christopher Patusky | Director | July 30, 2025 |
| Christopher Patusky | Director | July 30, 2025 |
|  | Director |  |
| Louis Sullivan | Director |  |
| /s/ Tommy Thompson | Director | July 30, 2025 |
| Tommy Thompson | Director | July 30, 2025 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107.1**

CALCULATION OF FILING FEE TABLES

**Form S-8**

(Form Type)

**United Therapeutics Corporation**

(Exact Name of Registrant as Specified in its Charter)

TABLE 1 – NEWLY REGISTERED SECURITIES

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Security Type** | &nbsp;&nbsp;**Security Class Title**  | &nbsp;&nbsp;**Fee Calculation Rule** | &nbsp;&nbsp;**Amount Registered**<sup>(1)</sup> | &nbsp;&nbsp;**Proposed Maximum Offering Price Per Unit** | &nbsp;&nbsp;**Maximum Aggregate Offering Price** | &nbsp;&nbsp;**Fee Rate** | &nbsp;&nbsp;**Amount of Registration Fee** |
| &nbsp;&nbsp;Equity | &nbsp;&nbsp;Common Stock, par value $0.01 per share | &nbsp;&nbsp;457(a) | &nbsp;&nbsp;950000<sup>(2)</sup> | &nbsp;&nbsp;$305.18<sup>(2)</sup> | &nbsp;&nbsp;$289921000<sup>(2)</sup> | &nbsp;&nbsp;$153.10 per $1,000,000 | &nbsp;&nbsp;$44386.91 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | &nbsp;&nbsp;$289921000 |  | &nbsp;&nbsp;$44386.91 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | &nbsp;&nbsp;$0 |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | &nbsp;&nbsp;$44386.91 |

---

(1) &nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of the common stock, par value $0.01 per share ("Common Stock"), of United Therapeutics Corporation that may be issued under the Amended and Restated United Therapeutics Corporation 2015 Stock Incentive Plan (the "Plan") as a result of any stock dividend, stock split, recapitalization or other similar transactions.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Represents 950,000 shares of Common Stock reserved for issuance under the Plan. The "Proposed Maximum Offering Price Per Unit" and the "Maximum Aggregate Offering Price" are estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, and are based upon the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Select Market for July 24, 2025.

## Exhibit 5.1

![gdc.jpg](gdc.jpg)

**Exhibit 5.1** 

July 30, 2025

United Therapeutics Corporation

1000 Spring Street

Silver Spring, Maryland 20910

Re: *Proposed Offering of up to 950,000 Shares of Common Stock Pursuant to the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan*

Ladies and Gentlemen:

&nbsp;&nbsp;&nbsp;&nbsp;

We have examined the Registration Statement on Form S-8 (the "Registration Statement") of United Therapeutics Corporation, a Delaware public benefit corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to 950,000 shares of the Company's Common Stock, par value $0.01 per share (the "Shares"). The Shares subject to the Registration Statement are to be issued under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the "Plan").

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinion set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to this opinion, we have relied to the extent we deemed appropriate and without independent investigation upon statements and representations of officers and other representatives of the Company and others. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plan that would expand, modify or otherwise affect the terms of the Plan or the respective rights or obligations of the participants thereunder.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor in accordance with the terms set forth in the Plan as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

**Gibson, Dunn & Crutcher LLP**<br> 1700 M Street, N.W. \| Washington, D.C. 20036-4504 \| T: 202.955.8500 \| F: 202.467.0539 \| gibsondunn.com

------

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson, Dunn & Crutcher LLP

**Gibson, Dunn & Crutcher LLP**<br> 1700 M Street, N.W. \| Washington, D.C. 20036-4504 \| T: 202.955.8500 \| F: 202.467.0539 \| gibsondunn.com

## Exhibit 23.1

**<br>Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement (Form S-8), dated July 30, 2025, pertaining to the Amended and Restated 2015 Stock Incentive Plan of United Therapeutics Corporation of our reports dated February 26, 2025, with respect to the consolidated financial statements and schedule of United Therapeutics Corporation and the effectiveness of internal control over financial reporting of United Therapeutics Corporation included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Tysons, Virginia

July 30, 2025

<br>